Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Pulmonary hypertension
PH and lung diseases
- Contact eczema
Causes and prevention at work
- Respiratory infections: viral bronchitis or bacterial pneumonia?
Old crucial question in the light of current findings
- What biomarkers reveal about "biological youth" - and what not (yet)
Epigenetic ageing
- Amyotrophic lateral sclerosis and nutrition
Calorie optimization in ALS through digital intervention
- "Forgotten axis" between plant substances, gut and systemic health
Microbiome and phytotherapy
- HIV: updated EACS guideline
Individualized approach to sustainable prevention and care
- Evidence-based diagnostics and treatment in the medical setting